Lyell Immunopharma competitors

Dr. James Breitmeyer is the president & CEO Oncternal Therapeutics, Inc., a San Diego cancer biotechnology company. He was instrumental in identifying and acquiring rights to ROR1 technology from UCSD and for developing ETS-family inhibitors based on discoveries from Georgetown University, while assembling Oncternal’s pipeline of oncology therapeutics. Dr. Breitmeyer was a lead author on the research grant submitted to the California Institute for Regenerative Medicine (CIRM) which resulted in the award of $18.3 million to UCSD to support development of lead program cirmtuzumab currently in Phase 1/2 clinical studies. Dr. Breitmeyer believes biomedical research and collaborations with academia are essential for targeting cancers where there are patients with critical unmet needs that aren’t being fully addressed by currently available therapies. At Oncternal, Dr. Breitmeyer is combining drug development expertise with exciting science for a synergistic combination to spur the development of novel product candidates that can potentially be applied across a large number of cancers. Dr. Breitmeyer is board certified in internal medicine and oncology. He holds a bachelor’s degree in chemistry from the University of California and earned M.D. and Ph.D. degrees from Washington University School of Medicine with fellowships at Washington University and Harvard Medical School. He held clinical and teaching faculty positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer has more than 30 years of experience across all aspects of the biotechnology industry in both large and small companies, and across multiple therapeutic areas. He is currently a member of the Boards of Directors of Oncternal Therapeutics Inc, Zogenix Inc, and Otonomy Inc.

Serge Saxonov is the founder and chief executive officer of 10X Genomics. Prior to that, he was the vice president for applications at QuantaLife. Saxonov holds a PhD in biomedical informatics from Stanford University. He has also studied applied mathematics at Harvard University. Saxonov lives in San Francisco, California, United States.

Alex Franzusoff is the chief executive officer of PACT Pharma. Prior to his current position, Alex served as the chief scientific officer and senior vice president of Research and Product Development of the company. Before joining PACT Pharma, he served as the founding CEO of Krypton Immuno-oncology, Inc. He also held executive positions at Bavarian Nordic, Inc, AZTherapies Inc., Permeon Biologics, Inc, and GlobeImmune.

Dr. Lara S. Sullivan is the Chief Executive Officer of Pyxis Oncology. Prior to joining Pyxis, Lara was Founder and President of SpringWorks Therapeutics (NASDAQ: SWTX), a clinical stage biopharmaceutical company spun-out from Pfizer. While at Pfizer, Lara led strategy, competitive intelligence and portfolio operations for the company’s early-stage R&D pipeline. Prior to joining Pfizer, Lara was an associate partner at McKinsey & Company, where she specialized in biopharmaceutical R&D productivity and efficiency. Lara also served as a principal at Paul Capital Partners, where she led due diligence for healthcare investments, and earlier in her career worked in healthcare equity research and healthcare municipal finance at Credit Suisse First Boston. Lara holds an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School at the University of Pennsylvania, and a B.A. in Comparative Literature from Cornell University.